REFERENCES
- Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Ann NY Acad Sci 1998; 850: 251–269, [INFOTRIEVE]
- Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, Prescott E, Wonke B. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91(1)295–300, [INFOTRIEVE], [CSA]
- Barman Balfour JA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in β-thalassemia major and other transfusion dependent diseases. Drugs 1999; 58(3)553–578, [INFOTRIEVE], [CROSSREF], [CSA]
- Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000; 108(2)305–312, [INFOTRIEVE], [CROSSREF], [CSA]
- Carthew P, Smith AG, Hider RC, Dorman B, Edwards RE, Francis JE. Potentiation of iron accumulation in cardiac myocytes during the treatment of iron overload in gerbils with the hydroxypyridinone iron chelator CP 94. Biometals 1994; 7(4)267–271, [INFOTRIEVE], [CROSSREF], [CSA]
- Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron R, McClelland RA, Burt A, Fleming K. Long-term safety and effectiveness of iron chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339(7)417–423, [INFOTRIEVE], [CROSSREF], [CSA]
- Kontoghiorghes GJ, Pattichi K, Hadjigabriel M, Kolnagou A. Transfusional iron overload and chelation therapy with Deferoxamine and deferiprone (L1). Transfus Sci 2000; 23(3)211–223, [INFOTRIEVE], [CROSSREF], [CSA]
- Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, Gamberini R, Schwartz E, Cohen AR. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent β-thalassemia. Blood 2002; 100(5)1566–1569, [INFOTRIEVE], [CROSSREF], [CSA]
- Wanless IR, Sweeney G, Dhillon AP, Guido M, Piga A, Galanello R, DeSanctis V, Schwartz E, Cohen A. Absence of deferiprone-induced hepatic fibrosis: a multi-center study. Blood 2000; 96: 606a, [CSA]
- Scarle J, Kerr J, Halliday J, Powell L. Iron storage disease. Pathology of the Liver, R MacSween, P Anthony, P Scheuer, A Burt, B Portmann. Churchill Livingstone, Edinburgh 1994; 219–241
- Borgna-Pignatti C, Rugolotto S, De Stefano P, Piga A, Di Gregorio F, Gamberini MR, Sabato V, Melevendi C, Cappellini MD, Verlato G. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998; 850: 227–231, [INFOTRIEVE], [CROSSREF], [CSA]
- Motckitis RJ, Martell AE. Stabilization of the iron (III) chelates of 1,2-dimethyl-3-hydroxypyrid-4-ones and related ligands. Inorg Chim Acta 1991; 183: 71–80, [CROSSREF], [CSA]
- Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, Wonke B. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995; 91(1)224–229, [INFOTRIEVE], [CSA]